


**THIRD
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

1

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			
 AUG 21 2003		<i>Complete If Known</i>	
		Application Number	10/054,616
		Filing Date	January 22, 2002
		First Name of Inventor	Larry S. BARAK et al.
		Examiner Name	Unassigned
		Attorney Docket Number	033072-022
Sheet	1	of	1

RECEIVED
AUG 22 2003
2003
TECH CENTER ANDREWS

Examiner Initials _____ Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

MOP ALEWIJNSE, ASTRID E., et al., *The Effect of Mutations in the DRY Motif on the Constitutive Activity and Structural Instability of the Histamine H₂ Receptor*, *Molecular Pharmacology*, 2000, pp. 890-898, 57, American Society for Pharmacology & Experimental Therapeutics, 0026-895X/00/050890, Baltimore, MD

**Examiner
Signature**

MICHAEL PAPKOVICH

Date
Considered

9-15-05

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO

JUL 19 2002

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

ATTORNEY'S DKT NO.
033072-022APPLICATION NO.
10/054,616

APPLICANT

Larry S. Barak, et al.

FILING DATE

January 22, 2002

GROUP

1645

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
MDP	6,150,393		Behan, et al.	11-21-2000
↑	6,140,509		Behan, et al.	10-31-2000
↓	6,110,693		Barak, et al.	08-29-2000
	6,107,324		Behan, et al.	08-22-2000
	6,066,476		Tsien, et al.	05-23-2000
	5,891,646		Barak, et al.	04-06-1999
	5,777,079		Tsien, et al.	07-07-1998
	5,767,337		Roses, et al.	06-16-1998
	5,719,262		Buchardt, et al.	02-17-1998
	5,714,331		Buchardt, et al.	02-03-1998
	5,665,710		Rahman, et al.	09-09-1997
↓	5,625,048		Tsien, et al.	04-29-1997
MDP	5,602,240		De Mesmaeker, et al.	02-11-1997

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No
MDP	WO 00/12704	A2	PCT	03-09-2000		
↑	WO 96/40062	A1	PCT	12-19-1996		
↓	WO 94/26764	A1	PCT	11-24-1994	<input checked="" type="checkbox"/>	<input type="checkbox"/>
MDP	WO 93/24510	A1	PCT	12-09-1993	<input checked="" type="checkbox"/>	<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MDP	ANGERS, S., et al., <i>Detection of β_2-Adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)</i> , <i>Proceedings of the National Academy of Sciences</i> , Vol 97, No. 7, March 28, 2000, pp. 3684-3689, Proc.Natl. Acad. Sci, USA.			
↑	ATTRAMADAL, H., et al., <i>β-Arrestin2, a Novel Member of the Arrestin/ β-Arrestin Gene Family</i> , <i>Journal of Biological Chemistry</i> , Vol 257, No. 25, September 5, 1992, pp 17882-17890, The American Society for Biochemistry and Molecular Biology, Inc., USA.			
	BARAK, L.S., et al., <i>A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation</i> , <i>Journal of Biological Chemistry</i> , Vol. 272, No. 44, October 31, 1997, pp. 27497-27500, The American Society for Biochemistry and Molecular Biology, Inc., USA.			
↓	BARAK, L.S., et al., <i>Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus</i> , <i>Proceedings of the National Academy of Sciences</i> , Vol 98, No. 1, January 2, 2001, pp. 93-98, Proc.Natl. Acad. Sci, USA.			
MDP	BARAK, L.S., et al., <i>Internal Trafficking and Surface Mobility of a Functionally Intact β_2-Adrenergic Receptor-Green Fluorescent Protein Conjugate</i> , <i>Molecular Pharmacology</i> , 51, 1997, pp. 177-184.			
Examiner Signature	MICHAEL PARK	Date Considered	8/15/05	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT NO:
033072-022APPLICATION NO.
10/054,616

APPLICANT

Larry S. Barak, et al.

FILING DATE
January 22, 2002GROUP
1645

JUL 19 2002

RECEIVED
JUL 23 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
MDP	5,569,827		Kessous-Elbaz, et al.	10-29-1996
↑	5,569,824		Donehower, et al.	10-29-1996
	5,539,082		Nielsen, et al.	07-23-1996
	5,264,221		Tagawa, et al.	11-23-1993
	5,034,506		Summerton, et al.	07-23-1991
	4,816,567		Cabilly, et al.	03-28-1989
	4,816,397		Boss, et al.	03-28-1989
↓	4,493,795		Nestor, Jr., et al.	01-15-1985
MDP	4,342,566		Theofilopoulos, et al.	08-03-1982

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MDP	BARAK, L.S., et al., <i>Real-time Visualization of the Cellular Redistribution of G Protein-coupled Receptor Kinase 2 and β-arrestin 2 during Homologous Desensitization of the Substance P Receptor</i> , <i>Journal of Biological Chemistry</i> , Vol. 274, No. 11, March 12, 1999, pp. 7565-7569, The American Society for Biochemistry and Molecular Biology, Inc., USA.
↑	Current Protocols in Molecular Biology, Vol. 1, Section II, Supplement 24, 6.3.1-6.3.6, 1993, John Wiley & Sons, NY.
	DREWS, J., <i>Drug Discovery: A Historical Perspective</i> , <i>Science</i> , Vol. 287, March 17, 2000, pp. 1960-1964, American Association for the Advancement of Science, Washington, D.C.
	FERGUSON, S.S.G., et al., <i>G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins</i> , <i>Can. J. Physiol. Pharmacol.</i> , Vol. 74, 1996, pp. 1095-1110, NRC, Canada.
	FERGUSON, S.S.G., et al., <i>Role of Phosphorylation in Agonist-promoted β₂-Adrenergic Receptor Sequestration</i> , <i>Journal of Biological Chemistry</i> , Vol. 270, No. 42, October 20, 1995, pp. 24782-24789, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	HARADA, A., et al., <i>Altered microtubule organization in small-calibre axons of mice lacking tau protein</i> , <i>Nature</i> , Vol. 369, No. 6480, June 9, 1994, Macmillan Magazines, Ltd., London.
	KIM, K.-M., et al., <i>Differential Regulation of the Dopamine D₃ and D₄ Receptors by G Protein-coupled Receptor Kinases and β-arrestins</i> , <i>Journal of Biological Chemistry</i> , Vol. 276 No. 40, October 5, 2001, pp. 37409-37414, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	LAPORTE, S.A., et al., <i>The β₂-Adrenergic Receptor/βarrestin complex recruits the clathrin adaptor AP-2 during endocytosis</i> , <i>Proceedings of the National Academy of Sciences</i> , Vol. 96, No. 7, March 30, 1999, pp. 3712-3717, Proc. Natl. Acad. Sci., USA.
↓	LAPORTE, S. A., et al., <i>The Interaction of β-Arrestin with the AP-2 Adaptor Is Required for the Clustering of β₂-Adrenergic Receptor into Clathrin-coated Pits</i> , <i>Journal of Biological Chemistry</i> , Vol. 275, No. 30, July 28, 2000, pp. 23120-23126, The American Society for Biochemistry and Molecular Biology, Inc., USA.
MDP	LOHSE, M., et al., <i>β-Arrestin: A Protein That Regulates β-Adrenergic Receptor Function</i> , <i>Science</i> , Vol. 248, pp. 1547-1550, June 22, 1990.

Examiner Signature	MICHAEL PIAN	Date Considered	8/15/05
--------------------	--------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO. 033072-022	APPLICATION NO. 10/054,616
APPLICANT Larry S. Barak, et al.	
FILING DATE January 22, 2002	GROUP 1645

JUL 19 2002


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MDP	MÉNARD, L., et al., <i>Synergistic Regulation of β_2-Adrenergic Receptor Sequestration: Intracellular Complement of β_2-Adrenergic Receptor Kinase and β-Arrestin Determine Kinetics of Internalization</i> , <i>Molecular Pharmacology</i> , Vol. 51, No. 5, May 1997, pp. 800-808, The American Society for Pharmacology and Experimental Therapeutics.		
↑	MHAOUTY-KODJA, S., et al., <i>Constitutively Active Alpha-1b Adrenergic Receptor Mutants Display Different Phosphorylation and Internalization Features</i> , <i>Molecular Pharmacology</i> , Vol. 55, No. 2, February 1999, pp. 339-347, The American Society for Pharmacology and Experimental Therapeutics.		
	OAKLEY, R.H., et al., <i>Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization</i> , <i>Journal of Biological Chemistry</i> , Vol 274, No. 45, November 5, 1999, pp. 32248-32257, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
	OAKLEY, R.H., et al., <i>Differential Affinities of Visual Arrestin, β-Arrestin1, and β-Arrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of Receptors</i> , <i>Journal of Biological Chemistry</i> , Vol 275, No. 22, June 2, 2000, pp. 17201-17210, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
	OAKLEY, R.H., et al., <i>Molecular Determinants Underlying the Formation of Stable Intracellular G Protein-coupled Receptor - β-Arrestin Complexes after Receptor Endocytosis</i> , <i>Journal of Biological Chemistry</i> , Vol 276, No. 22, June 1, 2001, pp. 19452 - 19460, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
	PROBST, W.C., et al., <i>Sequence Alignment of the G-Protein Coupled Receptor of Superfamily</i> , <i>DNA and Cell Biology</i> , Vol. 11, No. 1, January & February 1992, pp. 1-20, Mary Ann Liebert, Inc. Publishers.		
	SADEGHI, H.M., et al., <i>Maturation of Receptor Proteins in Eukaryotic Expression Systems</i> , <i>Journal of Receptor & Signal Transduction Research</i> , Vol. 17, No 1-3, 1997, pp. 433-445, Marcel Dekker, Inc., USA.		
	SADEGHI, H., et al., <i>O-Glycosylation of the V2 vasopressin receptor</i> , <i>Glycobiology</i> , Vol 9, No. 7, pp. 731-737, 1999, Oxford University Press, Printed by the Sheridan Press, USA.		
	SCHÖNEBERG, T., et al., <i>Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide</i> , <i>Embo Journal</i> , Vol 15, No. 6, pp. 1283-1291, 1996, Oxford University Press.		
	SCHÖNEBERG, T., et al., <i>V2 Vasopressin Receptor Dysfunction in Nephrogenic Diabetes Insipidus Caused by Different Molecular Mechanisms</i> , <i>Human Mutation</i> , Vol 12, No. 3, pp. 196-205, 1998, Wiley-Liss, Inc.		
↓	SHI, W., et al., <i>Rhodopsin Arginine-135 Mutants Are Phosphorylated by Rhodopsin Kinase and Bind Arrestin in the Absence of 11-cis-Retinal</i> , <i>Biochemistry</i> , Vol 37, pp. 4869-4874, 1998, American Chemical Society, Washington, D.C.		
	ZHANG, J., et al., <i>Cellular Trafficking of G Protein-coupled Receptor/ β-Arrestin Endocytic Complexes</i> , <i>Journal of Biological Chemistry</i> , Vol 274, No. 16, April 16, 1999, pp. 10999-11006, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
MDP	ZHANG, J., et al., <i>A Central Role for β-Arrestins and Clathrin-coated Vesicle-mediated Endocytosis in β_2-Adrenergic Receptor Resensitization</i> , <i>Journal of Biological Chemistry</i> , Vol. 272, No. 43, October 24, 1997, pp. 27005-27014, The American Society for Biochemistry and Molecular Biology, Inc., USA.		
Examiner Signature	MICHAEL PHK	Date Considered	8/15/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED
JUL 23 2002
TECH CENTER 1600/2900

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.	
		Complete if Known	
		Application Number	10/054,616
		Filing Date	January 22, 2002
		First Named Inventor	BARAK, Larry S.
		Group Art Unit	1645 1646
		Examiner Name	Unknown
		Attorney Docket No: NRK.10022	
Sheet 1 of 1			



US PATENT DOCUMENTS

Examiner Initials*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
MDP	BIRNBAUMER, MARIEL, et al., "Molecular Cloning of the Receptor for Human Antidiuretic Hormone", Nature, vol. 357, no. 6376, pp. 333-335 (1992).	
MDP	ROSENTHAL, WALTER, et al., "Nephrogenic Diabetes Insipidus: A V2 Vasopressin Receptor Unable to Stimulate Adenylyl Cyclase", Journal of Biological Chemistry, vol. 268, no. 18, pp. 13030-13033 (1993).	
MDP	SIEGL, PETER K. S., et al., "In Vivo Pharmacology of L-158,809, a New Highly Potent and Selective Nonpeptide Angiotensin II Receptor Antagonist", Journal of Pharmacology and Experimental Therapeutics, vol. 262, no. 1, pp. 139-144 (1 July 1992).	

EXAMINER MICHAEL PAN

DATE CONSIDERED

8/15/05

Substitute for form 1449A/PTO

ATTORNEY'S Dkt No. 033072-022	APPLICATION NO. 10/054,616
APPLICANT Larry S. BARAK et al.	
FILING DATE January 22, 2002	GROUP 1645

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MDP	U.S. Patent Application No. 09/993,844, Robert H. Oakley, et al., <i>Modified G-Protein Coupled Receptors</i> , Filed on November 5, 2001, attorney docket no. 033072-026.		
MPP	U.S. Patent Application No. 09/489,554, Laura M. Bohn, et al., <i>Inhibition of B-arrestin Mediated Effects Prolongs and Potentiates Opioid Receptor-Mediated Analgesia</i> , Filed on December 22, 1999, attorney docket no. 033072-017.		
	(DO NOT PRINT)		
Examiner Signature	MICHAEL PITT	Date Considered	8/15/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

BEST AVAILABLE COPY